JP2013511287A5 - - Google Patents

Download PDF

Info

Publication number
JP2013511287A5
JP2013511287A5 JP2012540160A JP2012540160A JP2013511287A5 JP 2013511287 A5 JP2013511287 A5 JP 2013511287A5 JP 2012540160 A JP2012540160 A JP 2012540160A JP 2012540160 A JP2012540160 A JP 2012540160A JP 2013511287 A5 JP2013511287 A5 JP 2013511287A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
composition according
diabetes
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012540160A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013511287A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/057890 external-priority patent/WO2011063414A1/en
Publication of JP2013511287A publication Critical patent/JP2013511287A/ja
Publication of JP2013511287A5 publication Critical patent/JP2013511287A5/ja
Pending legal-status Critical Current

Links

JP2012540160A 2009-11-23 2010-11-23 ポリペプチド・コンジュゲート Pending JP2013511287A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26375209P 2009-11-23 2009-11-23
US61/263,752 2009-11-23
PCT/US2010/057890 WO2011063414A1 (en) 2009-11-23 2010-11-23 Polypeptide conjugate

Publications (2)

Publication Number Publication Date
JP2013511287A JP2013511287A (ja) 2013-04-04
JP2013511287A5 true JP2013511287A5 (cg-RX-API-DMAC7.html) 2013-11-14

Family

ID=44060086

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012540160A Pending JP2013511287A (ja) 2009-11-23 2010-11-23 ポリペプチド・コンジュゲート

Country Status (11)

Country Link
US (1) US20140066370A1 (cg-RX-API-DMAC7.html)
EP (1) EP2504021A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013511287A (cg-RX-API-DMAC7.html)
KR (1) KR20120116942A (cg-RX-API-DMAC7.html)
CN (1) CN102781458A (cg-RX-API-DMAC7.html)
AU (1) AU2010321587A1 (cg-RX-API-DMAC7.html)
CA (1) CA2781672A1 (cg-RX-API-DMAC7.html)
IL (1) IL219948A0 (cg-RX-API-DMAC7.html)
MX (1) MX2012005912A (cg-RX-API-DMAC7.html)
RU (1) RU2012126101A (cg-RX-API-DMAC7.html)
WO (1) WO2011063414A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104945499B (zh) * 2014-03-31 2019-12-10 博瑞生物医药(苏州)股份有限公司 结构修饰的glp-1类似物及其制备方法
TWI802396B (zh) * 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN106554404B (zh) * 2015-09-25 2020-11-20 博瑞生物医药(苏州)股份有限公司 艾塞那肽修饰物及其用途
KR20230034356A (ko) * 2020-07-02 2023-03-09 사노피 활성이 감소된 glp-1r 효능제 펩티드
TWI850611B (zh) * 2020-12-18 2024-08-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP2002505338A (ja) 1998-03-05 2002-02-19 カイロン コーポレイション 生物学的に活性な分子の血清半減期を増加するための方法
EP1143989B1 (en) 1999-01-14 2006-12-13 Amylin Pharmaceuticals, Inc. Exendins for glucagon suppression
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
DE60006100T2 (de) 1999-05-17 2004-07-01 Conjuchem, Inc., Montreal Lang wirkende insulinotrope peptide
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
BRPI0507623A (pt) 2004-02-11 2007-07-03 Amylin Pharmaceuticals Inc peptìdeos da famìlia da amilina e métodos para prepará-los e empregá-los
CN102174115B (zh) 2004-02-11 2014-05-14 安米林药品有限责任公司 具有可选择特性的杂合多肽
US7465234B2 (en) * 2004-09-13 2008-12-16 The Boeing Company Hybrid fastening system and associated method of fastening
US20090286723A1 (en) * 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
BRPI0606992A2 (pt) * 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
JP2009504681A (ja) * 2005-08-11 2009-02-05 アミリン・ファーマシューティカルズ,インコーポレイテッド 選択可能な特性を有するハイブリッドポリペプチド
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
JP2009523177A (ja) 2006-01-11 2009-06-18 ブリストル−マイヤーズ スクイブ カンパニー ヒトグルカゴン様ペプチド−1調節因子、並びに糖尿病および関連症状の治療におけるその使用
MX2008012666A (es) 2006-03-31 2008-10-13 Amylin Pharmaceuticals Inc Amilina y agonistas de amilina para tratar enfermedades y trastornos psiquiatricos.
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
EP2636680A3 (en) * 2006-05-26 2013-12-11 Amylin Pharmaceuticals, LLC Composition and methods for treatment of congestive heart failure
CN102827284B (zh) 2006-11-14 2015-07-29 上海仁会生物制药股份有限公司 带有聚乙二醇基团的Exendin或其类似物及其制剂和用途
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
EP2416797A4 (en) * 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE
US9249181B2 (en) * 2010-09-13 2016-02-02 Amylin Pharmaceuticals, Llc C-terminal amidation of polypeptides
US10755005B1 (en) 2015-12-31 2020-08-25 Dassault Systemes Solidworks Corporation Providing a single command to create multiple CAD features

Similar Documents

Publication Publication Date Title
RU2470016C2 (ru) Производное бипиразола
JP2011503152A5 (cg-RX-API-DMAC7.html)
JP2017505284A5 (cg-RX-API-DMAC7.html)
JP2009542702A5 (cg-RX-API-DMAC7.html)
FI4349369T3 (fi) Lääkkeen biologisen hyötyosuuden lisääminen naltreksonihoidossa
RU2016122957A (ru) Способы применения интерлейкина-10 для лечения заболеваний и расстройств
JP2011528333A5 (cg-RX-API-DMAC7.html)
JP2009542699A5 (cg-RX-API-DMAC7.html)
JP2013511287A5 (cg-RX-API-DMAC7.html)
JP2011225596A5 (cg-RX-API-DMAC7.html)
JP2018531938A5 (cg-RX-API-DMAC7.html)
JP2013509411A5 (cg-RX-API-DMAC7.html)
JP2013541583A5 (cg-RX-API-DMAC7.html)
JP2020536854A5 (cg-RX-API-DMAC7.html)
JP2017526695A5 (cg-RX-API-DMAC7.html)
RU2012126101A (ru) Полипептидный конъюгат
JP2015517458A5 (cg-RX-API-DMAC7.html)
JP2015508765A5 (cg-RX-API-DMAC7.html)
CA2944837A1 (en) Cyclohexenyl compounds, compositions comprising them and uses thereof
US20180221449A1 (en) Compositions for Changing Body Composition, Methods of Use, and Methods of Treatment
IL194500A0 (en) Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
JP2014500244A5 (cg-RX-API-DMAC7.html)
JP2013507382A5 (cg-RX-API-DMAC7.html)
JP2013507383A5 (cg-RX-API-DMAC7.html)